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Introduction
Lung transplant recipients are susceptible to infection
due to aggressive triple immunosuppressant regimens. To
prevent rejection, many laboratory studies are needed, in-
cluding monitoring of immunosuppressant levels and lung
function test. However, serum immunosuppressant levels
alone may not accurately reflect the patient's immune status.
Immuknow® (Cylex, Columbia, MD) is a novel in vitro
assay for measuring cell function of stimulated T cells1. We
report a case of invasive pulmonary aspergillosis (IPA)
after living donor lobar lung transplantation by monitoring
and controlling patients' immune status.
Case
A 43-year-old woman underwent living donor lobar lung
transplantation for pulmonary alveolar proteinosis. One donor
was her old brother, whose left lower lobe was donated. The
other donor was her husband for right lower lobe. Both do-
nors were apparently healthy. Her postoperative course was
uneventful, and she was discharged without oxygen support.
She had been receiving a standard triple immunosuppressant
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We report a case that was successfully treated invasive pulmonary aspergillosis after living donor lobar lung transplantation
and monitored patients' immune function with ImmuKnow® assay. A 43-year-old woman underwent living donor lobar lung
transplantation for pulmonary alveolar proteinosis. Two healthy her relatives donated each lower lobe. Six months after trans-
plantation, she was diagnosed as invasive pulmonary aspergillosis (IPA). During the anti-fungal treatment, one immunosuppressant
was withdrawn and the trough level of calcineurin inhibitor was reduced to the minimum. Despite of such a low
immunosuppressive status, Immuknow® assay showed that immune function was maintained in the moderate range, which
encouraged us to keep this strategy for IPA. Immune evaluation by Immuknow® is useful method for monitoring and controlling
patients' immune status especially in the infected condition, which revealed moderate immune level could be maintained with
only two immunosuppressant drugs in the patient after recovery from IPA.
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regimen, including tacrolimus, mycophenolate mofetil (1500
mg / body), and prednisolone (0.4mg / kg for the first six
months, following 0.2 mg / kg). The prophylaxis for fungal
infection was oral itraconazole 100 mg daily. Six months after
transplantation, she developed a nonproductive cough, and
chest CT showed multiple nodular shadows, mainly involv-
ing the right lung (Fig. 1). CT-guided lung biopsy was done,
and these nodules were found to be Aspergillus fumigatus.
Thus, she was diagnosed as having IPA. Mycophenolate
mofetil was withdrawn immediately, and the trough level
of tacrolimus was reduced to around 5 - 8 ng/ml to allow
the patient's immune status to recover to battle the infec-
tion. The patient was treated with oral voricocazole 300 mg
twice daily, inhalation of amphotericin B 10 mg 5 times daily,
and intravenous micafungin 300 mg daily. Fortunately, her
condition improved over 3 months of hospitalization, and
she was discharged without any symptoms. Oral voriconazole
and inhaled amphotericin B were continued as prophylaxis
for 9 months. A follow-up chest CT showed complete reso-
lution of the multiple nodular shadows (Fig. 2). The details
of this case were reported previously2.
The patient's immune function was measured using the
Immuknow® assay during the convalescent period (from 14
to 19 months after transplantation) (Fig. 3). Local ethics
committee approval was obtained prior to commencement
of this study. The patient gave her written, informed con-
sent. During this period, T-cell immune function was mod-
erate. After recovery from IPA, the patient's immune func-
tion still remained within the moderate range despite the
discontinuation of one immunosuppressant. No rejection or
other infection was seen during this period. Also, her FEV1.0
(forced expiratory volume in one second) remained stable
during the treatment (Fig. 4).
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Figure 1. Chest CT shows multiple nodular shadows (arrows).
CT-guided lung biopsy found that these shadows were sites of
Aspergillus fumigatus infection.
Figure 3. The gray bar shows the immune function level from 14
month to 19 months after transplantation during the recovery
phase from invasive pulmonary aspergillosis (IPA). During this
period, T-cell immune function was moderate. Immune function
remained within the moderate range after recovery from IPA 14
months after the infection. The line plot shows tacrolimus trough
levels, which were controlled at a low level (around 5 - 8 ng/ml).
The horizontal lines represent cutoffs for strong (525 ng/ml ATP),
moderate (524 - 226 ng/ml ATP), and low immune function (225
ng/ml ATP).
Figure 2. Invasive pulmonary aspergillosis can be seen to have
been successfully treated by oral voriconazole, micafungin injec-
tion, amphotericin B inhalation, and reducing immunosuppressant
therapy under monitoring with the ImmuKnow® function test.
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Discussion
This is a report of immune function monitoring during
the treatment of IPA after living donor lobar lung trans-
plantation. Our report highlights two important facts: moni-
toring of immune function is effective and reliable during
treatment for IPA after lung transplantation; and just two
immunosuppressant drugs, a calcineurin inhibitor and a
steroid, can maintain moderate immune function after liv-
ing donor lobar lung transplantation.
Lung transplant recipients have the highest rate of infec-
tion among solid organ transplant recipients3. Moreover, re-
jection, both acute and chronic, remains a major problem.
Long-term survival after lung transplantation is hindered by
infection and lung allograft rejection4. Therefore, a number
of parameters are monitored after transplantation to prevent
or identify early complications related to lung transplanta-
tion in the hope of reducing morbidity and mortality. These
include routine laboratory studies, imaging, surveillance
lung biopsy, and monitoring of immunosuppressant levels
and lung function. Monitoring of serum immunosuppressant
levels allows individualization of patients' immunosuppressant
therapy. However, immunosuppressant levels alone may
not reflect the patient's immune status5. Immuknow® (Cylex,
Columbia, MD) is a novel in vitro assay for measuring cell
function of stimulated T cells, which has been licensed by
the Food and Drug Administration for monitoring the immune
system of transplant patients1. It functions on the principle
of incubating target T cells with phytohemagglutinin and
measuring the production of intracellular ATP as a reflection
of cell metabolism6. Immune status is expressed as strong
(525 ng / ml ATP), moderate (524 - 226 ng / ml ATP), and
low immune function (225 ng / ml ATP). Recently, there
have been some reports of the use of this assay in clinical
lung transplantation2-4, 7. These reports indicate that know-
ing the immune function could help determine who may be
at risk for infection or rejection. Bhorade et al5 assessed the
functional immune response by the ImmuKnow® assay in
143 sequential blood samples from 57 lung transplant recipi-
ents and reported that the ImmuKnow® assay levels were
lower in infected lung transplant recipients compared with
non-infected recipients.
In the present case, the patient had received standard
triple immunosuppressant therapy (calcineurin inhibitor,
mycophenolate mofetil, and steroid). However, 6 months
after transplantation, the patient developed IPA, which has
been believed to be a fatal disease after lung transplantation8.
At first, she was started on voriconazole 600 mg and
micafungin injections for IPA. Simultaneously, mycophenolate
mofetil was stopped, and reduction of the trough level of
calcineurin inhibitor was started to recover from the
immunosuppressed status. On the other hand, during treat-
ment, we became very concerned that the patient may de-
velop chronic rejection due to reduced immunosuppression.
Thus, we started to measure immune function using the
ImmuKnow® assay. This assay showed that immune func-
tion was maintained in the moderate range, which encour-
aged us to reduce the immunosuppressant to the lowest
possible level though most of the monitoring was under-
taken after the disease was almost under control.
Optimization of the dosages of immunosuppressants is a
constant dilemma. Patients suffer rejection for a long pe-
riod during their lives, possibly because of fluctuations in
immune status with low-level immunosuppression. On the
other hand, patients are susceptible to infection because of
frequent exposure to infectious air-borne microorganisms
(bacterial, viral, fungal, and protozoal) with high level
immunosuppression. In addition, triple immunosuppressant
regimens result in a number of morbidities, including hy-
pertension, renal dysfunction, diabetes, and post-transplant
lymphoproliferative disease. To date, there is no clinical
evidence to support maintaining lung transplant patients on
less than three immunosuppressant drugs. Based on the pre-
sent data, the patient's immune function remained within the
moderate range despite use of only two immunosuppressant
drugs, tacrolimus and prednisolone, after recovery from IPA.
When monitoring the immune status using ImmuKnow® is
possible, an immunosuppressant regimen that consists of
only tacrolimus and prednisolone might be better to
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Figure 4. There was no decline of the forced expiratory volume
in one second after transplantation despite in the period of
aspergillus infection (arrows). FEV1.0 = Forced expiratory vol-
ume in one second, pre = pre operation
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maintain immune function and reduce the side effects of
mycophenolate mofetil when chronic infection develops. In
general, most living donor lobar lung transplantations are
undertaken between relatives and extensive immunologic
matching may take place beforehand, to select the appropri-
ate donor. Also it can be expected, under these circum-
stances, that the likelihood of rejection and need for
immunosuppressant drugs may be less.
Conclusion
Though this is just a case report, immune evaluation
by Immuknow® might be a useful method for monitoring
patients' immune status. This method showed that a moder-
ate immune status could be maintained with only two
immunosuppressants in a patient with chronic IPA infec-
tion. Further study is needed to determine the role of
Immuknow® in optimizing the immune status of lung trans-
plant patients.
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